The groundbreaking rise of Viagra has consistently remained a benchmark of pharmaceutical success, however its future within the broader sector now triggers questions about future returns . Copycat versions are eroding exclusivity , prompting concerns that supporting companies closely tied to Viagra's once-dominant influence could be a speculative